Time in Range vs A1C: Which Metric Matters More?

Understanding the Two Key Diabetes Metrics

For decades, the A1C test was the gold standard for measuring diabetes control. But with the rise of continuous glucose monitors (CGMs), a newer metric called Time in Range (TIR) is changing how patients and clinicians think about blood sugar management. So which number matters more? The honest answer: both do — but for different reasons.

What Is A1C?

A1C measures your average blood glucose over the past two to three months by looking at how much glucose has attached to hemoglobin in your red blood cells. A result below 7% is generally considered the target for most adults with diabetes. It's a well-established predictor of long-term complications like neuropathy, retinopathy, and kidney disease.

However, A1C has a significant blind spot: it tells you the average, not the full story. Two people can have the same A1C of 7% — one with stable, consistent glucose levels and another with wild swings between dangerous highs and lows. A1C cannot distinguish between the two.

What Is Time in Range?

Time in Range refers to the percentage of time your glucose levels stay within a target range — typically 70 to 180 mg/dL for most people with diabetes. This metric is only possible with a CGM sensor, which tracks glucose continuously throughout the day and night.

International guidelines recommend that people with Type 1 or Type 2 diabetes aim for at least 70% Time in Range, which translates to roughly 17 hours per day within target. TIR also tracks time spent in hypoglycemia (below 70 mg/dL) and hyperglycemia (above 180 mg/dL), giving a far more complete picture of glucose variability.

Why Time in Range Is Gaining Ground

Research increasingly supports TIR as a meaningful predictor of diabetes-related complications. Studies have shown that higher TIR correlates with lower rates of diabetic retinopathy and reduced cardiovascular risk — outcomes previously associated only with A1C. Unlike A1C, TIR can detect dangerous glucose swings and hypoglycemic episodes that an average simply masks.

For patients using CGM technology, TIR provides real-time, actionable data. You can see how a specific meal, workout, stress event, or medication change immediately affects your glucose patterns — something an A1C result taken every three months simply cannot offer.

When A1C Still Matters

A1C remains a critical metric in clinical settings, especially for patients who do not use CGMs. It is widely available, inexpensive, and backed by decades of research linking it to complication risk. Many insurance coverage decisions and treatment guidelines are still anchored to A1C targets.

Additionally, A1C is useful for identifying longer-term trends that short CGM wear periods might miss. If you've only worn a CGM sensor for 14 days, your TIR data may not fully represent your overall glucose control across different seasons, routines, or life stressors.

Which Metric Should You Focus On?

The most effective approach is to use both metrics together. Think of A1C as the big-picture snapshot and TIR as the daily detail that helps you make smart adjustments. If your A1C looks good but your TIR is low, it's a red flag that your glucose may be swinging unpredictably — even if the average appears acceptable.

For those exploring CGM options and wanting guidance on the latest sensor technology, resources like mdsdiabetes.com offer up-to-date information on CGM devices and how to interpret your glucose data effectively.

The Bottom Line

Neither A1C nor Time in Range alone tells the complete story of your diabetes management. A1C provides a reliable long-term average, while TIR reveals the daily variability that drives real health outcomes. Together, they give you and your care team the clearest possible view of your glucose control — empowering smarter, more personalized diabetes care decisions.